In Vivo Pharma Intelligence | The Growth Path for Drug Discovery Partners
Nov 2022
Originally published by In Vivo Pharma Intelligence on November 15, 2022
James West, Director in Lincoln’s Healthcare Group, explains the key trends and mergers and acquisitions (M&A) dynamics in the drug discovery industry.
Summary
-
James West, Director in Lincoln’s Healthcare Group, shares with In Vivo Pharma Intelligence the key trends and M&A dynamics in the drug discovery industry.
- Sign up to receive Lincoln's perspectives
Contributor
Related Perspectives
Investors in Healthcare | Q&A with Lincoln Professionals
Originally posted by Investors in Healthcare on July 25, 2024. Lincoln International, the U.S.-headquartered global investment banking advisor, is a well-known name in the European healthcare markets, providing advice to… Read More
Outlook in the EU: PE has Ophthalmology Sector in its Sights
Across Europe, private clinics and specialist outpatient healthcare providers such as ophthalmology practices have seen a wave of consolidation, which has led to the emergence of several pan-European and more… Read More
Real Deals | Maintaining Momentum: The Outlook for M&A in the Healthcare Sector
Originally posted by Real Deals on May 31, 2024. RD: Which sub-sector of healthcare is currently attracting the most investment? Dirk-Oliver Löffler: Provider business is still one of the core… Read More
PETS International | Consolidation Meets Regulation in the Veterinary Clinics Market
Originally posted by PETS International on April 5, 2024. Animal health is becoming a big business in Europe and the U.S. Thus, regulators are turning a closer eye to mergers… Read More
